PYSC 181 Lecture 7

Introduction to Opioids: Terminology, Classification, and Formulations

• Pharmacological Classification and Terminology

  • Opioids: Any compound possessing opiate-like pharmacological actions. This is a broad, overarching category encompassing natural opiates, semi-synthetic compounds, and fully synthetic substances.

  • Opiates: Naturally occurring alkaloid compounds derived directly from the opium poppy plant (Papaver somniferum). Examples include morphine, codeine, and thebaine.

  • Narcotics: Pharmacologically defined strictly as any analgesic substance that induces sleepiness or profound sedation.

  • In legal and law enforcement contexts (e.g., the Drug Enforcement Administration [DEA]), the term "narcotic" is loosely applied to any highly controlled or scheduled drug regardless of pharmacology, including cocaine and marijuana.

  • In true pharmacology, cocaine (a stimulant) and marijuana (a cannabinoid) are explicitly not narcotics.

  • Opium: The raw sap or "milk of the poppy" exuded when the unripe seed capsules (pods) of the opium poppy are incised or slashed. The resulting white, viscous latex is collected, compressed into small cakes, and dried for use.

  • Morphine: The principal active chemical constituent and primary natural opiate in opium, responsible for its core pharmacological effects.

• Three Major Structural Categories of Opioids

  • Naturally Occurring Opioids (Opiates): Chemical compounds directly harvested from opium poppy sap.

  • Includes opium, morphine, codeine, and thebaine.

  • Semi-Synthetic Opioids: Compounds synthesized by chemically modifying the molecular structure of a naturally occurring opiate.

  • Hydrocodone: Synthesized/derived from codeine.

  • Oxycodone: Synthesized/derived from thebaine.

  • Heroin (Diacetylmorphine): Synthesized/derived from morphine.

  • Fully Synthetic Opioids: Compounds fabricated entirely via chemical synthesis from scratch in a laboratory setting. They do not originate from natural plant precursors, though they are designed to mimic opiate molecular configurations and actions.

  • Includes fentanyl and methadone.

• Desomorphine and Toxic Adulteration ("Krokodil")

  • Composition: Krokodil is an illicit, crude synthetic opioid mixture containing desomorphine (synthesized from codeine) combined with toxic industrial chemicals such as Drano (lye), gasoline, paint thinner, and battery acid.

  • Pathology: Intravenous administration produces severe localized tissue necrosis, extreme phlebitis, and gangrene, resulting in a black, scaly, flesh-eating skin condition.

  • Cognitive Impact: Produces severe cognitive debilitation and CNS disruption.

  • Nomenclature and Confusion: Termed "zombie heroin" due to the physical appearance of rotting tissue on living users.

  • Often confused in pop culture with synthetic cathinones ("bath salts") due to news reports of erratic behaviors. Synthetic cathinones are amphetamine-like CNS stimulants, whereas Krokodil is a necrotizing desomorphine-based opioid mixture. Krokodil does not induce anthropophagy (eating human flesh); its designation stems purely from the severe flesh-eating dermatological damage it inflicts.

• Formulations, Combinations, and Route Potency

  • Combination Drugs: Products combining an opioid with non-opioid analgesics to enhance pain relief. For example, Vicodin consists of hydrocodone combined with acetaminophen.

  • Route-Dependent Potency Factors:

  • Oxycodone: Demonstrates higher potency than morphine when administered orally, but lower potency than morphine when administered intravenously ($\text{IV}$).

  • Morphine: Exhibits low lipid solubility and undergoes significant ionization and enzymatic degradation during first-pass hepatic metabolism, drastically reducing its oral bioavailability relative to parenteral routes.

  • Actiq (Fentanyl Transmucosal Formulation):

  • Formulated as a transmucosal lollipop for controlled clinical delivery.

  • Transmucosal absorption avoids first-pass hepatic destruction and prevents frequent intravenous access line destruction caused by repetitive injection of basic opioid compounds.

  • Transdermal Formulations: Fentanyl patches provide slow, continuous rate-controlled delivery across the skin barrier.

Pharmacokinetics and Receptors of Opioids

• Absorption and Distribution

  • Chemical Nature: Most opioid compounds are weak bases. Consequently, oral administration leads to variable absorption and destruction within the acidic gastric environment relative to parenteral administration (transdermal, sublingual, or injection).

  • Lipid Solubility: With the exception of morphine (which has low lipid solubility), most opioids are highly lipophilic.

  • Tissue Barriers: Highly lipophilic opioids rapidly cross both the blood-brain barrier ($\text{BBB}$) and the placental barrier.

  • Elimination: Extensively metabolized by hepatic enzymes and primarily excreted via renal filtration into urine.

  • Metabolic Interactions: Absorption and clearance rates are altered by exogenous substances that interact with metabolic pathways, including caffeine, grapefruit juice (a cytochrome $P_{450}$ inhibitor), and St. John's wort.

• Opioid Receptor Subtypes

  • Opioids exert actions by binding to three primary metabotropic G-protein coupled receptors ($\text{GPCRs}$):

  • $\mu$ (Mu) Receptor: The central mediator for primary therapeutic analgesia, euphoria/reward, respiratory depression, and physical dependence.

  • $\kappa$ (Kappa) Receptor: Mediates spinal analgesia, dysphoria, psychotomimetic effects, and hallucination.

  • $\delta$ (Delta) Receptor: Mediates peripheral analgesia and modulates $\mu$ receptor activity.

  • Reclassification Note: Historical literature listed a fourth subtype, the $\sigma$ (Sigma) receptor; however, it is no longer classified as a true opioid receptor due to distinct binding characteristics and non-opioid pharmacological profiles.

• Endogenous Opioids and Neuropeptide Synthesis

  • Endogenous ligands (e.g., endorphins, enkephalins, dynorphins) are produced naturally within the body to modulate pain and stress pathways.

  • Neuropeptides vs. Classical Neurotransmitters:

  • Classical Neurotransmitters (e.g., dopamine, serotonin): Derived from dietary amino acid precursors (such as tyrosine), modified by enzymatic cascades within the axon terminal, and packaged into synaptic vesicles. Cells generally synthesize a single predominant classical transmitter type.

  • Neuropeptides: Directly transcribed from nuclear genes as large precursor proteins (pro-peptides) and translated at the ribosome. Post-translational proteolytic cleavage yields families of functional peptide variants that may differ by only one or two amino acids.

  • A single peptidergic neuron generates multiple distinct, closely related neuropeptide variants from a single gene precursor family.

• General Cellular Mechanism of Action

  • Opioid receptor activation is predominantly inhibitory at the cellular level.

  • Binding to $\text{GPCRs}$ causes hyperpolarization of the neuronal membrane (via activation of $\text{K}^+$ efflux channels) and suppression of presynaptic voltage-gated $\text{Ca}^{2+}$ channels, inhibiting neurotransmitter release.

  • Disinhibition Phenomena: Inhibitory opioid signals on inhibitory interneurons (e.g., $\text{GABA}$ergic cells) produce a net excitatory downstream physiological effect.

  • Anatomical Sites: Receptors are distributed throughout both the Central Nervous System (CNS) (dorsal horn, brainstem, thalamus, hypothalamus, ventral tegmental area) and Peripheral Nervous System (PNS) (gastrointestinal tract primary afferent neurons).

Behavioral Effects, Pain Mechanisms, and Nociception

• Three Primary Behavioral Effects Driven by $\mu$ Receptors

  • Analgesia: Relief from sensory pain signals and affective emotional distress.

  • Reward and Pleasure: Activation of central reward circuits, producing intense euphoria and reducing symptoms of anxiety and depression (similarly activated during endogenous endorphin release from exercise).

  • Sedation: Profound central nervous system depression. Opioids do not induce physiological, restful sleep architecture; chronic use impairs normal sleep structure and promotes severe rebound insomnia via opponent-process adaptations.

• Clinical Analgesic Spectrum by Pain Severity

  • Mild to Moderate Pain: Codeine, Tramadol, Hydrocodone.

  • Hydrocodone has historically been one of the most widely prescribed pharmaceutical substances in the United States.

  • Moderate to Severe Pain: Demerol (meperidine), Oxycodone.

  • Severe Chronic or Severe Traumatic Pain: Heroin, Hydromorphone (indicated for major neurological trauma, crushed nerves, and limb amputations).

• Ancillary and Systemic Side Effects

  • Respiratory Depression: The most dangerous and life-threatening side effect. Opioids suppress the brainstem respiratory centers' sensitivity to blood carbon dioxide levels, leading to hypoventilation, respiratory arrest, and death.

  • Cough Suppression (Antitussive): Suppression of the medullary cough reflex center, preventing tissue damage and hemorrhage in severe pulmonary conditions.

  • Gastrointestinal Motility Decreases: Severe inhibition of peristalsis leading to profound constipation.

  • Users do not develop tolerance to gastrointestinal constipation.

  • Therapeutically exploited by synthetic opioid analogs like loperamide (Imodium), which acts selectively on peripheral GI mu-receptors without crossing the blood-brain barrier, treating diarrhea safely.

• The Pain Onion Model and Nociceptive Processing

  • Pain processing consists of three distinct, overlapping levels:

  • 1. Nociception: The physiological reception and transmission of noxious sensory signals via peripheral nociceptive primary afferents.

  • 2. Pain Perception: The top-down processing and interpretation of nociceptive signals by cortical and subcortical structures.

    • Phantom Limb Pain: Demonstrates perception occurring without nociception; amputees experience severe perceived limb pain despite the complete absence of peripheral nociceptors.

  • 3. Suffering: The subjective, negative affective emotional valence and psychological distress attributed to pain through cognitive self-reflection (e.g., emotional grief, heartbreak, or severe depression).

  • Opioids act concurrently across all three levels: directly blocking nociceptive input at the spinal cord, suppressing central pain perception, and blunting the affective suffering response.

• Spinal Nociceptive Gating Mechanism

  • Primary afferent pain fibers enter the spinal cord via the dorsal horn.

  • Opioid receptors are concentrated directly within the substantia gelatinosa of the dorsal horn. No other sensory modalities (touch, proprioception) utilize opioid receptors at this primary spinal entry gate.

  • Opioid administration shuts off dorsal horn transmission neurons, halting incoming nociceptive signals before they travel up the spinothalamic tract to the brain.

• $\mu_1$ vs. $\mu_2$ Receptor Subtypes and Knockout Studies

  • $\mu_1$ ($\text{MOR}_1$) Receptor Subtype: Primary site mediating analgesia.

  • Pretreatment with a selective $\mu_1$ antagonist blocks analgesia, shifting the morphine analgesic dose-response curve to the right by $12\text{ times}$ ($12\times$ higher dose required for equivalent pain relief).

  • Morphine vs. Heroin Pharmacodynamics:

  • Historically, differences were attributed strictly to pharmacokinetics (heroin's higher lipid solubility allows faster crossing of the $\text{BBB}$).

  • Genetic knockout mouse studies ($\text{MOR}_1$ knockouts) demonstrate pharmacodynamic differences as well:

    • In homozygous $\text{MOR}_1$ knockout mice ($-/-$), morphine's analgesic effect is completely eliminated ($0$ response).

    • In contrast, morphine-6-glucuronide ($\text{M6G}$), an active metabolite closely linked to heroin's pathway, retains significant analgesic efficacy in $\text{MOR}_1$ knockouts.

Opioid Reinforcement, Toxicity, Tolerance, and Addiction Treatments

• Neurobiology of Opioid Reinforcement

  • Reinforcing properties are mediated primarily via $\mu$ receptor sites located within the ventral tegmental area ($\text{VTA}$) and nucleus accumbens/anterior cingulate cortex ($\text{ACC}$).

  • Disinhibition Mechanism:

  • Under basal conditions, $\text{GABA}$ergic interneurons continuously exert tonic inhibition over dopaminergic projection neurons in the $\text{VTA}$.

  • Opioids bind to $\mu$ receptors expressed directly on these local $\text{GABA}$ interneurons, hyperpolarizing them and stopping $\text{GABA}$ release.

  • Removal of $\text{GABA}$ inhibition (disinhibition) causes an increase in dopaminergic neuron firing rate in the $\text{VTA}$, elevating dopamine release in the nucleus accumbens to produce reward.

  • Lesioning dopaminergic pathways or co-administering dopamine receptor antagonists significantly impairs opioid self-administration and conditions place preference ($\text{CPP}$).

  • Other Receptor Roles:

  • Selective $\delta$ receptor activation produces weak analgesia and minor reinforcement.

  • Selective $\kappa$ receptor activation (e.g., by benzomorphans) induces dysphoria, severe psychotomimetic reactions, and intense hallucinations, making $\kappa$ agonists strongly aversive.

• Respiratory Depression Mechanisms and Receptor Knockout Studies

  • Opioid-induced respiratory depression is driven predominantly by $\mu_2$ receptor activation in brainstem cardiorespiratory centers.

  • In combined $\mu_1$ and $\mu_2$ knockout mice ($\text{MOR}$ double knockouts), all classical opioid effects—analgesia, reward, respiratory depression, withdrawal signs, GI dysmotility, and psychoactive actions—are completely abolished.

  • Knocking out $\delta$ or $\kappa$ receptors alone does not abolish $\mu$-mediated reward or analgesia.

• Tolerance Mechanisms and Hyperalgesia

  • Tolerance develops through both functional (receptor desensitization, internalisation, downregulation) and metabolic (enzymatic induction) processes.

  • Cross-tolerance develops readily between different opioid compounds (e.g., morphine, codeine, heroin) and partially extends to ethanol.

  • Opioid-Induced Hyperalgesia ($\text{OIH}$):

  • Chronic administration of opioids can induce a paradoxical sensitization to pain, rendering users hyper-responsive to painful stimuli.

  • Mechanism involves persistent suppression of spinal nociceptive gating, leading to down-regulation and apoptosis (cell death) of dorsal horn opioid receptors.

  • When the drug wanes, baseline inhibition is diminished, leaving the patient with heightened sensitivity to pain.

• Opioid Withdrawal Syndrome

  • Physiological withdrawal resembles a severe, debilitating influenza-like illness, featuring lacrimation, rhinorrhea, severe muscle/abdominal cramping, hyperthermia, vomiting, diarrhea, intense agitation, sweating, and insomnia.

  • Onset occurs within 6–24 hours post-cessation, peaking within 48–72 hours, and generally subsides over 1–2 weeks.

  • Although severe and unpleasant, uncomplicated opioid withdrawal is rarely acutely fatal (unlike severe alcohol or barbiturate withdrawal).

• Pharmacological Interventions for Opioid Use Disorder (OUD)

  • Methadone:

  • A fully synthetic, long-acting $\mu$-opioid receptor agonist administered orally once daily.

  • Exhibits very high receptor binding affinity. When methadone occupies the receptors, it competitively blocks shorter-acting opioids (e.g., heroin) from binding, attenuating euphoria if a relapse occurs.

  • Slow oral absorption prevents rapid surges in blood levels, avoiding intense euphoria while preventing withdrawal distress and cravings.

  • Patients do not readily develop tolerance to methadone's maintenance dose, eliminating the need for continuous escalation.

  • Buprenorphine:

  • A partial $\mu$-opioid agonist with a long half-life and strong binding affinity.

  • Displays a ceiling effect for respiratory depression, enhancing clinical safety.

  • Because it is a partial agonist, it produces less maximal operational intrinsic activity, which can lead to lower withdrawal relief and reduced patient compliance compared to methadone.

  • Heroin-Assisted Therapy (HAT):

  • Physician-supervised administration of pharmaceutical-grade heroin (diacetylmorphine) offered in countries such as the United Kingdom and Canada.

  • Clinical trials demonstrate higher treatment retention, lower overall mortality, reduced illicit drug use, and decreased criminal activity compared to oral methadone programs.

  • Antagonist Therapies:

  • Naloxone: A competitive opioid receptor antagonist with rapid onset and short duration. Used acutely to displace agonists from $\mu$ receptors to reverse life-threatening respiratory depression during an overdose; precipitates immediate, severe withdrawal.

  • Naltrexone: A long-acting competitive antagonist utilized for long-term relapse prevention after detox is complete.

  • Suboxone: A combination formulation of buprenorphine and naloxone designed to prevent intravenous abuse.

  • Taken sublingually, buprenorphine is absorbed while naloxone exhibits minimal oral/sublingual bioavailability.

  • If dissolved and injected intravenously, naloxone blocks the buprenorphine effect and triggers immediate withdrawal.

Introduction to Alcohol: Chemistry, Absorption, and Distribution

• Chemical Classification

  • Alcohols constitute a broad class of organic chemical compounds containing one or more hydroxyl ($\text{-OH}$) moieties.

  • Non-Ingested Alcohols:

  • Isopropyl Alcohol (rubbing alcohol): Toxic solvent causing severe systemic toxicity if ingested.

  • Methanol (methyl alcohol / wood alcohol): Metabolized into formaldehyde and formic acid, inducing optic nerve necrosis (blindness), severe metabolic acidosis, and death.

  • Ingested Alcohol: Ethyl alcohol (ethanol / grain alcohol, $\text{C}_2\text{H}_5\text{OH}$).

  • Produced naturally via yeast fermentation of simple sugars. Unchecked prolonged fermentation oxidizes ethanol into acetic acid (vinegar).

• Pharmacokinetics of Absorption

  • Route: Almost exclusively ingested orally; absorbed across the gastric mucosa (~$20\%$) and upper small intestine (~$80\%$).

  • Intestinal Rate: The small intestine possesses a much larger vascularized surface area than the stomach, leading to rapid systemic entry once alcohol exits the stomach through the pyloric sphincter.

  • Gastric Emptying & Food Interactions:

  • Ethanol is a non-ionizable molecule; physiological $\text{pH}$ changes across the gastrointestinal tract do not alter its absorption profile.

  • Food consumption prior to or alongside drinking delays gastric emptying, keeping alcohol inside the stomach longer where absorption is slow. This slows systemic entry and significantly flattens peak Blood Alcohol Concentration ($\text{BAC}$).

  • Ingesting alcohol on an empty stomach triggers rapid gastric emptying into the duodenum, producing a sharp, elevated peak $\text{BAC}$.

  • Inhalation / Vaping Danger: Vaporized ethanol bypasses gastrointestinal processing and hepatic first-pass metabolism, directly entering pulmonary circulation and reaching the brain in seconds, creating a high risk of fatal overdose.

• Biphasic Effects and Distribution

  • Alcohol exerts biphasic behavioral effects depending on the physiological trajectory of $\text{BAC}$:

  • Rising $\text{BAC}$ Limb: Characterized by psychomotor stimulation, euphoria, social disinhibition, and talkativeness.

  • Falling $\text{BAC}$ Limb / Plateau: Characterized by sedation, motor ataxia, cognitive dulling, and lethargy.

  • Distribution: Highly water-soluble; distributes uniformly throughout total body water compartments. Does not accumulate in adipose tissue.

  • Barrier Permeability: Easily crosses both the blood-brain barrier and placental barrier.

  • Excretion: Small proportions ($2 - 10\%$) are excreted unchanged via exhaled breath (providing the quantitative basis for breathalyzer testing), sweat, and urine.

• Fetal Alcohol Spectrum Disorders (FASD)

  • Alcohol exposure during pregnancy is the leading preventable cause of developmental and neurocognitive disability in children.

  • Pathological Features: Central nervous system dysfunction including microcephaly, impaired fine motor skills, impulsivity, hyperactivity, severe executive function deficits, and low $IQ$.

  • Craniofacial / Physical Malformations: Smooth philtrum, thin upper lip, small palpebral fissures, skeletal malformations, cardiac septal defects, and auditory impairments.

  • Cellular Mechanism: Ethanol acts as a potent $\text{NMDA}$ glutamate receptor antagonist and $\text{GABA}_A$ receptor agonist, triggering widespread apoptotic neurodegeneration during critical embryonic neurodevelopmental windows. Developing fetuses lack functional alcohol dehydrogenase ($\text{ADH}$) enzymes and rely on slow maternal/hepatic clearance.

Alcohol Metabolism, Dosage, and Neurochemical Mechanisms

• Hepatic Metabolic Cascades

  • Metabolism occurs primarily in the liver through two enzymatic steps:

$\text{Ethanol} \xrightarrow{\text{Alcohol Dehydrogenase (ADH)}} \text{Acetaldehyde} \xrightarrow{\text{Aldehyde Dehydrogenase (ALDH)}} \text{Acetic Acid} \rightarrow \text{Water } (\text{H}_2\text{O}) + \text{Carbon Dioxide } (\text{CO}_2)$

• Acetaldehyde Toxicity: Acetaldehyde is a reactive intermediate metabolite. Deficiencies in aldehyde dehydrogenase ($\text{ALDH}$) cause an accumulation of acetaldehyde, triggering severe flushing, nausea, tachycardia, hyperventilation, and headache.

• Microsomal Ethanol Oxidizing System (MEOS):

  • An alternative metabolic pathway utilizing cytochrome $P_{450}$ enzymes (specifically $CYP2E1$).

  • Recruited during heavy chronic alcohol intake, causing enzyme induction that increases metabolic clearance rates.

  • Shares metabolic pathways with barbiturates, leading to cross-tolerance.

  • Factors Influencing Metabolism and Absorption Rates

• Gastric ADH Levels: Medications such as $H_2$-receptor blockers (heartburn drugs) and aspirin inhibit stomach $\text{ADH}$ activity, reducing pre-systemic first-pass metabolism and significantly increasing resulting $\text{BAC}$.

• Beverage Concentration: The rate of passive absorption increases with alcohol concentration up to a ceiling of approximately $40\%$ ($80\text{ proof}$). Higher concentrations delay gastric emptying by irritating the gastric mucosa, slowing absorption.

• Carbonation: Carbonated alcoholic beverages accelerate gastric emptying, forcing contents rapidly into the small intestine and hastening absorption.

  • Standard Drink Metrics and Legal Limits

• Legal Limit for Driving: In the United States, the threshold for illegal operational impairment is a $\text{BAC}$ of $0.08\,\text{g/dL}$ ($80\,\text{mg/dL}$ or $0.08\%$ $\text{BAC}$). This limit was established based on epidemiological motor vehicle crash risk data across age demographics.

• Standard Drink Definition: Contains approximately $14\,\text{grams}$ of pure ethanol:

  • Beer: $12\,\text{fl oz}$ (~$5\%$ alcohol content).

  • Malt Liquor: $8\,\text{fl oz}$ (~$7\%$ alcohol content).

  • Table Wine: $5\,\text{fl oz}$ (~$12\%$ alcohol content; transcript references $5.8\,\text{fl oz}$ context).

  • 80-Proof Distilled Spirits: $1.5\,\text{fl oz}$ shot (~$40\%$ alcohol content).

• Metabolic Rate: The liver metabolizes approximately $1\text{ standard drink per hour}$. Peak $\text{BAC}$ is reached approximately $30\text{ minutes}$ post-ingestion on an empty stomach.

  • Dose-Dependent Physiological and Behavioral Effects

• $100 - 150\,\text{mg/dL}$ ($0.10 - 0.15\%$ $\text{BAC}$): Expressed behavioral disinhibition, euphoric mood, altered emotionality, impairment of fine motor coordination.

• $150 - 300\,\text{mg/dL}$ ($0.15 - 0.30\%$ $\text{BAC}$): Pronounced sensory loss, motor ataxia, major slurring of speech, severe reaction time delay, lethargy.

• $300 - 400\,\text{mg/dL}$ ($0.30 - 0.40\%$ $\text{BAC}$): Severe cognitive stupor, loss of voluntary motor control, anterograde amnesia (blackouts), loss of consciousness.

• $> 400\,\text{mg/dL}$ ($> 0.40\%$ $\text{BAC}$): Lethal toxicity threshold; induce central respiratory depression, coma, and autonomic collapse.

  • Neurochemical Systems Affected by Alcohol

• 1. $\text{GABA}$ System ($\text{GABA}_A$ Receptors):

  • $\text{GABA}$ is the brain's primary inhibitory neurotransmitter.

  • Ethanol functions as a Positive Allosteric Modulator (PAM) at ionotropic $\text{GABA}_A$ receptors, increasing $\text{Cl}^-$ ion channel opening frequency/duration and hyperpolarizing neurons.

  • Cortical/Prefrontal Inhibition: Blunts executive decision-making, planning, and impulse control.

  • Subcortical Inhibition: Suppresses autonomic arousal and processing speed.

  • Cerebellar Inhibition: Disrupts motor balance and gait stability.

  • Chronic exposure leads to neuroadaptive down-regulation of $\text{GABA}_A$ receptors.

• 2. Glutamate System ($\text{NMDA}$ Receptors):

  • Glutamate is the brain's primary excitatory neurotransmitter.

  • Ethanol directly inhibits ionotropic $\text{NMDA}$ glutamate receptors by blocking the channel pore, impairing synaptic plasticity and memory formation.

  • Chronic exposure triggers homeostatic up-regulation of $\text{NMDA}$ receptors.

• 3. Endogenous Opioid System:

  • Ethanol stimulates the indirect synthesis and release of endogenous endorphins, mediating euphoric and analgesic properties.

• 4. Dopamine System:

  • Ethanol enhances mesolimbic dopamine release in the nucleus accumbens via $\text{VTA}$ $\text{GABA}$ interneuron disinhibition.

  • Co-Ingestion with Stimulants (e.g., Caffeinated Alcoholic Beverages)

• Products like the original Four Loko formulation (banned in 2010 containing $12 - 15\%$ $\text{ABV}$ combined with high doses of caffeine, taurine, and guarana) present serious physiological hazards.

• Masking Mechanism: Caffeine acts as an $\text{A}_{2A}$ adenosine receptor antagonist, masking the subjective perception of depressant/sedative symptoms without lowering $\text{BAC}$ or improving motor coordination.

• Users feel deceptively alert, overrides natural satiety signals, drink higher volumes of alcohol, and engage in high-risk behaviors or suffer lethal acute toxicity.

Chronic Alcohol Use, Toxicity, Withdrawal, and AUD Therapies

• Forms of Tolerance

  • Acute Tolerance: A phenomenon where subjective intoxication is experienced as more intense on the ascending limb of the $\text{BAC}$ curve than on the descending limb at an identical numerical $\text{BAC}$ level.

  • Behavioral Tolerance: Learned cognitive/motor compensation performed by experienced individuals under the influence of alcohol. Applies only to simple motor tasks (e.g., walking a straight line during a field sobriety test) and does not extend to complex psychomotor tasks like operating a vehicle.

  • Cross-Tolerance: Chronic alcohol consumption produces cross-tolerance to other $\text{GABA}_A$ positive allosteric modulators, including benzodiazepines and barbiturates.

• Alcohol Withdrawal Syndrome and Delirium Tremens

  • Alcohol withdrawal is highly dangerous and can be fatal.

  • Mild to Moderate: Hangover effects, tremor, agitation, tachycardia, hypertension, gastrointestinal distress, sweating, and insomnia.

  • Severe Withdrawal / Delirium Tremens (DTs):

  • Occurs in chronic dependent individuals following abrupt cessation of drinking.

  • Driven by down-regulated $\text{GABA}_A$ receptors combined with up-regulated $\text{NMDA}$ receptors, leading to uninhibited CNS hyperexcitability.

  • Symptoms include extreme confusion, disorientation, severe hyperthermia, auditory/visual hallucinations, autonomic instability, and status epilepticus (grand mal seizures).

  • Requires immediate, continuous medical supervision and management (typically using long-acting benzodiazepines).

• Pathophysiological Risks of Chronic Alcohol Abuse

  • Hepatic Pathology: Progresses from reversible fatty liver (steatosis) to alcoholic hepatitis, culminating in Cirrhosis (irreversible fibrous tissue scarring and liver failure). Severe cirrhosis requires a liver transplant, which is contraindicated without documented long-term sobriety.

  • Korsakoff's Syndrome:

  • A neurodegenerative amnestic disorder caused by severe thiamine ($\text{Vitamin B}_1$) deficiency.

  • Frequently occurs in chronic alcoholics who obtain a majority of daily calories from nutrient-poor alcoholic beverages.

  • Characterized by irreversible anterograde and retrograde amnesia, severe confabulation, and lesions within the mammillary bodies and medial dorsal thalamus.

  • Carcinogenesis: Highly correlated with malignant neoplasms across the gastrointestinal tract, including cancers of the mouth, pharynx, larynx, esophagus, liver, and colon.

• Risk Factors for Alcohol Use Disorder (AUD)

  • Elevated Risk: Family history of $\text{AUD}$, high baseline tolerance (low-level response to alcohol where large quantities are consumed before feeling intoxicated), high trait impulsivity, and co-occurring psychiatric disorders.

  • Decreased Risk: Experiencing primarily sedating/dysphoric symptoms upon drinking, or inheriting $\text{ALDH}$ enzyme variants that cause rapid, uncomfortable flushing/nausea.

• Therapeutic Interventions for AUD

  • Behavioral Interventions: Individual psychotherapy, Cognitive Behavioral Therapy ($\text{CBT}$), and 12-step mutual aid groups (Alcoholics Anonymous). Interventions target cognitive restructuring, identifying emotional and environmental relapse triggers, and developing adaptive coping mechanisms.

  • Pharmacological Therapies:

  • Acamprosate: A structural analog of $\text{GABA}$ that normalizes hyperactive glutamatergic transmission post-withdrawal, reducing alcohol craving.

  • Disulfiram (Antabuse): A structural inhibitor of Aldehyde Dehydrogenase ($\text{ALDH}$). Ingesting alcohol while taking disulfiram causes an immediate accumulation of toxic acetaldehyde, inducing violent nausea, facial flushing, vomiting, and severe headache to conditioned aversion.

Fact vs. Myth: Alcohol Phenomena and Physiological Realities

• 1. Drinking Coffee Sobers You Up: FALSE

  • Caffeine is a central nervous system stimulant ($\text{A}_{2A}$ adenosine antagonist) that increases alertness but does not alter hepatic $\text{ADH}$ metabolism, clear blood alcohol, or restore impaired motor and cognitive functions.

  • Result: Combines intoxication with heightened wakefulness (an "awake drunk").

• 2. "Beer Goggles" (Increased Perceived Attractiveness): TRUE

  • Alcohol blunts visual acuity and spatial processing. Cortical processing fills in visual details, reducing the perception of facial asymmetry or physical flaws and altering social judgment.

• 3. "Beer Jacket" (Alcohol Warms the Body): FALSE / PARADOXICAL

  • Hepatic ethanol metabolism generates a minor internal heat sensation, and ethanol induces peripheral vasodilation (dilation of surface blood vessels).

  • Vasodilation flushes warm blood to the skin, producing a subjective feeling of warmth, but rapid heat radiation from the body surface accelerates core hypothermia in cold environments.

• 4. "Breaking the Seal" (Peeing Once Causes Continuous Urination): FALSE

  • Urination frequency is driven by neuroendocrine mechanisms, not an anatomical threshold.

  • Ethanol directly inhibits the secretion of Anti-Diuretic Hormone ($\text{ADH}$ / vasopressin) from the posterior pituitary gland.

  • Without $\text{ADH}$, renal collecting ducts fail to reabsorb water, triggering fluid loss regardless of whether a person delays initial urination.

• 5. "Beer Armor" (Alcohol Blunts Pain / Increases Resilience): TRUE

  • Ethanol stimulates endogenous opioid release and suppresses dorsal horn nociceptive transmission, raising physical pain thresholds and blunting pain perception.

• 6. Drinks Taste Better the More You Drink: TRUE (QUALIFIED)

  • Ethanol blunts gustatory receptor sensitivity and olfactory perception over time.

  • As gustatory processing is blunted, the bitter or unpleasant taste of concentrated alcohol becomes less perceptible.

• 7. Nightcaps Improve Sleep Quality: FALSE

  • While alcohol's sedating properties ($\text{GABA}_A$ activation) hasten sleep onset, it disrupts sleep architecture throughout the night.

  • Suppresses Rapid Eye Movement ($\text{REM}$) sleep, alters deep slow-wave sleep, and induces sympathetic rebound in the second half of the night, causing fragmented, non-restorative sleep.

Questions & Discussion

• Audience Question: Does the milky sap that comes out of the opium poppy pod resemble the stem latex of a fig tree, and is there any physiological connection?

  • Response: The milky white sap exuded when slashing an unripe poppy pod is raw opium itself. The color and physical latex appearance are common plant structural characteristics (similar to tree sap or blood in human vasculature) and do not determine pharmacological activity. Opioid action is defined strictly by the chemical structure of the alkaloids contained within the sap, not its physical latex properties or color.

• Audience Question: Can the unprocessed, natural poppy plant produce opioid effects directly without chemical processing?

  • Response: Yes. Raw poppy sap is opium. Chemical refinement is not required to produce opioid effects. Raw sap is dried and flattened into cakes purely for physical storage and ease of administration (combustion/smoking), analogous to pressing cannabis trichomes into hashish.

• Audience Question: What is the general immediate cellular effect of opioid receptor activation on neurons?

  • Response: Opioid receptor activation is fundamentally inhibitory at the cellular level. Any downstream excitatory effects (such as increased dopaminergic firing in the reward circuit) are achieved through disinhibition—the inhibition of an inhibitory cell system.

• Audience Question: Could an externally administered peptide affect post-translational processing or converting enzymes of endogenous neuropeptides?

  • Response: Neuropeptide synthesis and post-translational enzymatic processing cascades are complex and less fully mapped than classical neurotransmitter pathways. While exogenous peptides could theoretically interact with these enzymes, the exact regulatory mechanisms remain an active area of research.

• Audience Question: Can a person be legally prosecuted in their home state if they travel to another jurisdiction (e.g., Canada or the UK) to receive Heroin-Assisted Therapy ($\text{HAT}$)?

  • Response: Receiving a medical treatment in a jurisdiction where it is legally sanctioned does not violate drug possession laws in the home state, provided no controlled substances are transported across international borders. This differs from specific state statutes that target extra-jurisdictional activities.

• Audience Question: What physiological process causes cutaneous flushing ("rosacea-like redness") when certain individuals drink alcohol?

  • Response: Cutaneous flushing is primarily caused by an inherited deficiency or altered activity in the enzyme Aldehyde Dehydrogenase ($\text{ALDH}$). This deficiency slows down the conversion of acetaldehyde into acetic acid, causing toxic acetaldehyde to build up in the bloodstream. Acetaldehyde triggers systemic histamine release and peripheral vasodilation, resulting in facial redness, warmth, increased heart rate, and nausea.